Friday, July 10, 2026

pharma · Hepatocellular Carcinoma · Acute Lymphoblastic Leukemia

Anhui Provincial Hospital

Anhui Provincial Hospital clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
2
Drugs
5
Patents
0
Intelligence · Clinical Programs

Anhui Provincial Hospital projects

2 ClinicalTrials.gov programs sponsored by Anhui Provincial Hospital.

Anhui Provincial Hospital has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Donafenib + Envafolimab

    Anhui Provincial Hospital

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial
  2. Metabolically Armed CD19 CAR-T cells

    Anhui Provincial Hospital

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anhui Provincial Hospital have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.